Drug-induced autoimmune hepatitis caused by anti-tumor necrosis factor α agents

Hepatology

Volumn 52, Issue 6, 2010, Pages 2246-2247

  Efe, Cumali ^a   Purnak, Tugrul ^a   Ozaslan, Ersan ^a   Wahlin, Staffan ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; LIVER ENZYME; MINOCYCLINE; NITROFURANTOIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; DRUG INDUCED AUTOIMMUNE DISEASE; DRUG INDUCED AUTOIMMUNE HEPATITIS; DRUG INDUCED DISEASE; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LIVER FAILURE; LIVER FUNCTION TEST; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; TOXIC HEPATITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS HEPATITIS; VIRUS REACTIVATION;

CLINICAL ENZYME TESTS; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; MINOCYCLINE; NITROFURANTOIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649572324     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23834     Document Type: Letter

References (14)

1. Björnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. HEPATOLOGY 2010; 51: 2040-2048.
2. Tobon GJ, Cañas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol 2007; 26: 578-581.
3. Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 2010; 44: e20-e22.
4. Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, Priori R, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1519-1520.
5. Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2009; 76: 84-86.
6. Saleem G, Li SC, MacPherson BR, Cooper SM. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. Arthritis Rheum 2009; 44: 1966-1968.
7. Ozorio G, McGarity B, Back H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 2009; 187: 524-526.
8. Marques M, Magro F, Cardoso H, Carneiro F, Portugal R, Lopes J, et al. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis 2009; 14: 723-725.
9. Becker H, Willeke P, Domschke W, Gaubitz M. Etanercept tolerance in a patient with previous infliximab-induced hepatitis. Clin Rheumatol 2009; 27: 1597-1598.
10. Thiefin G, Morelet A, Heurgue A, Diebold MD, Eschard JP. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 2009; 75: 737-739.
11. Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriasis. Clin Exp Dermatol 2009; 34: 421-422.
12. Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med 2010; 5: 193-200.
13. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005; 52: 2192-2201.
14. Yazdani-Biuki B, Stadlmaier E, Mulabecirovic A, Brezinschek R, Tilz G, Demel U, et al. Blockade of tumour necrosis factor α significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1224-1226.